Affiliation:
1. From the Center for Management Research in Healthcare; Management of Technology Program; Owen Graduate School of Management; Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN; and Cancer and Leukemia Group B, Chicago, IL
Abstract
Purpose National Cancer Institute–sponsored cooperative oncology groups are major sponsors of phase III clinical trials, yet the time and steps required to design and activate such studies has not been well studied. We examine the processes and document the calendar time required to activate such studies opened by the Cancer and Leukemia Group B (CALGB). Methods Setup steps were documented by (1) interviewing CALGB headquarters and statistical center staff and committee chairs to discover the steps required to transit from concept development to final study activation, (2) reviewing procedure manuals, and (3) inspecting all study records, documents, and e-mails to identify any additional steps. Calendar time was collected for each major process. Results Thirteen phase III studies were activated by CALGB during the study period of May 2002 to May 2005. More than 370 distinct processes were required for study activation: 317 work steps, 42 decision points, and 29 processing loops. Sixty-three percent of the decision points were outside CALGB. The complete process map measures 243.5” × 41” in 8-point font. Median calendar days to activate a phase III study at CALGB was 580 days (range, 295 to 1,248 days) from concept approval and 784 days (range, 537 to 1,130 days) from initial conception of the study. Conclusion Setup of a phase III study at a major cooperative oncology group is a complex and lengthy process, with the majority of decision points external to the cooperative group. To improve the activation process, research should to be directed toward both internal and external groups and processes.
Publisher
American Society of Clinical Oncology (ASCO)
Reference6 articles.
1. Improving the evaluation of new cancer treatments: challenges and opportunities
2. Invisible Barriers to Clinical Trials: The Impact of Structural, Infrastructural, and Procedural Barriers to Opening Oncology Clinical Trials
3. Fukuda H: Infrastructure of cancer clinical trial cooperative groups in western countries [Japanese]. Gan To Kagaku Ryoho 27:1144,2000-1151,
4. Harrington HJ: Business Process Improvement . New York, NY, McGraw-Hill, 1991
5. Gane C, Sarson T: Structured Systems Analysis: Tools and Techniques . Englewood Cliffs, NJ, Prentice-Hall, 1979
Cited by
69 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献